Hereditary spastic paraplegia linked to chromosome 14q11-q21: reduction of the SPG3 locus interval from 5.3 to 2.7 cM

Shirley Rainier, Peter Hedera, David Alvarado, Ximing Zhao, Kleopas A Kleopa, Terry Heiman-Patterson, John K Fink

Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA
S Rainier
P Hedera
D Alvarado
X Zhao
J K Fink

Department of Neurology, Hahneman University School of Medicine, Philadelphia PA, USA
K A Kleopa
T Heiman-Patterson

Geriatric Research Education Clinical Center, Ann Arbor Veteran's Affairs Medical Center, Ann Arbor, Michigan, USA
J K Fink

Correspondence to Dr Fink, Room 5214 CCGCB, 1500 E Medical Center Drive, Ann Arbor, Michigan 48109-0940, USA, jdkink@umich.edu

Table 1  Two point lod scores for markers at the SPG3 locus

<table>
<thead>
<tr>
<th>Marker</th>
<th>Penetrance</th>
<th>0</th>
<th>0.05</th>
<th>0.10</th>
<th>0.20</th>
<th>0.30</th>
<th>0.40</th>
</tr>
</thead>
<tbody>
<tr>
<td>D14S269</td>
<td>AFM267ad5</td>
<td>0.9</td>
<td>2.95</td>
<td>2.59</td>
<td>2.22</td>
<td>1.50</td>
<td>0.81</td>
</tr>
<tr>
<td>D14S748</td>
<td>CHLC.GATA90G11</td>
<td>0.9</td>
<td>2.30</td>
<td>2.08</td>
<td>1.85</td>
<td>1.39</td>
<td>0.86</td>
</tr>
<tr>
<td>D14S1068</td>
<td>AFM114xg7</td>
<td>0.9</td>
<td>4.19</td>
<td>3.81</td>
<td>3.41</td>
<td>2.56</td>
<td>1.68</td>
</tr>
<tr>
<td>D14S746</td>
<td>CHLC.GATA85A11</td>
<td>0.9</td>
<td>4.63</td>
<td>4.22</td>
<td>3.79</td>
<td>2.88</td>
<td>1.90</td>
</tr>
<tr>
<td>D14S1031</td>
<td>AFMb359zd1</td>
<td>0.9</td>
<td>0.78</td>
<td>0.71</td>
<td>0.63</td>
<td>0.46</td>
<td>0.31</td>
</tr>
<tr>
<td>D14S978</td>
<td>AFMab122ya5</td>
<td>0.9</td>
<td>0.08</td>
<td>1.63</td>
<td>1.71</td>
<td>1.41</td>
<td>1.01</td>
</tr>
</tbody>
</table>

Editor—Recently, Reid et al reported reduction of the chromosome 14q locus for autosomal dominant hereditary spastic paraplegia.

We now report reduction of the chromosome 14q locus for autosomal dominant hereditary spastic paraplegia (SPG3, OMIM 182600). Hereditary spastic paraplegia (HSP) (also known as Strümpell-Lorrain syndrome) is a heterogeneous group of disorders characterized by progressive lower extremity weakness and spasticity. Gait disturbance may begin at any age and progresses insidiously. Postmortem studies show axonal degeneration that is maximal in the distal ends of the corticospinal tracts and fasciculus gracilis fibres1-4 (website http://www.geneclinics.org).

Loci for autosomal dominant HSP have been identified on chromosomes 2p22 (SPG4), 2q24-34 (SPG13), 8q23-q24 (SPG8), 12q13 (SPG10), 10q23.3-q24.2 (SPG9), 14q11-q21 (SPG3), 15q11.1 (SPG6), and 19q13 (SPG12).5-10 Forty-five percent of kindreds with autosomal dominant, uncomplicated HSP are linked to the SPG4 locus on chromosome 2p22. Mutations in a novel gene (designated “spastin”) were recently discovered as the basis for chromosome 2p22 (SPG4) linked HSP.1 Spastin’s functions are unknown, although homology to 26S proteasome subunit and Sap1 proteins suggests that spastin participates in formation of nuclear protein complexes.

Approximately 15% of autosomal dominant, uncomplicated HSP is linked to the SPG3 locus on chromosome 14q11-21.1 This locus was identified initially by Hazan et al1 and subsequently reduced to the interval between D14S259 and D14S281 by Gispert et al.12 We performed two point linkage analysis using polymorphic microsatellite markers flanking and within the SPG3 locus. DNA samples were extracted from peripheral blood leukocytes and microsatellite markers were amplified and analyzed as previously described.13 We observed significantly negative two point lod scores for markers at HSP loci SPG4 (lod score for D2S352 = −6.45 at 0 = 0 and −2.02 at 0 = 0.10), SPG8 (lod score for D8S1799 = −3.44 at 0 = 0 and −1.90 at 0 = 0.05; lod score for D8S1138 = −4.79 at 0 = 0 and −1.99 at 0 = 0.05), and SPG6 (lod score for D1S5542 = −4.21 at 0 = 0; lod score for D15SS128 = −5.23 at 0 = 0 and −1.91 at 0 = 0.05). In contrast, we observed two point lod scores >+2.0 (table 1) for markers flanking and within the SPG3 locus on chromosome 14q11-21. The maximum two point lod score was +4.63 (0 = 0) for D14S746 (CHLC.GATA85A11). Three additional markers, D14S1068 (AFM114xg7), D14S269 (AFM267ad5), and D14S978 (CHLC.GATA90G11), also yielded two point lod scores greater than 2.0 (table 1). These observations indicated that the disorder in this family was linked to the SPG3 locus.

Subject III.1 (fig 1) shows a recombination between markers D14S1031 and D14S978. Since this subject is affected with HSP, the HSP gene mutation must be centromeric to D14S978. This defines the SPG3 critical region to a 2.7 cM region between D14S259 and D14S978 (fig 2). The reduction of the SPG3 locus from 5.3 cM to 2.7 cM restricts this locus to chromosome 14q21-q22 and will permit investigators to direct their search for candidate genes to this restricted region. Identification of the SPG3 gene will provide insight into the biochemical basis of HSP on which development of rational treatment depends.
This research was supported by grants from the Veterans Affairs Merit Review and the National Institutes of Health (NINDS R01NS33645, R01NS36177, and R01NS38713) to JKF. We gratefully acknowledge the expert secretarial assistance of Ms Lynette Girbach and the participation of HSP subjects and their families without whom our investigations of HSP would not be possible.

**Figure 1** HSP kindred linked to the SPG3 locus on chromosome 14q21-22.

**Figure 2** Autosomal dominant HSP locus (SPG3) on chromosome 14q21-22.

- Autosomal dominant hereditary spastic paraplegia (HSP) is genetically heterogeneous.
- Approximately 15% of such kindreds show genetic linkage to the SPG3 locus on chromosome 14q11-21.
- Analysis of one kindred with autosomal dominant HSP linked to the SPG3 locus showed an obligate recombination that reduced the SPG3 critical region to a 2.7 cM interval between D14S259 and D14S978.
- This information will facilitate discovery of the SPG3 gene.


Hereditary spastic paraplegia linked to chromosome 14q11-q21: reduction of the SPG3 locus interval from 5.3 to 2.7 cM

Shirley Rainier, Peter Hedera, David Alvarado, Xinping Zhao, Kleopas A Kleopa, Terry Heiman-Patterson and John K Fink

*J Med Genet* 2001 38: e39
doi: 10.1136/jmg.38.11.e39

Updated information and services can be found at:
http://jmg.bmj.com/content/38/11/e39

These include:

**References**

This article cites 17 articles, 6 of which you can access for free at:
http://jmg.bmj.com/content/38/11/e39#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Genetic screening / counselling (886)
- Clinical genetics (256)
- Neuromuscular disease (257)
- Peripheral nerve disease (97)
- Immunology (including allergy) (604)
- Molecular genetics (1254)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/